Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ireland-headquartered biopharmaceuticals firm Alltracel Pharmaceuticals has obtained preliminary results from patient trials indicating that M.doc is safe and effective as a cholesterol management agent.
Subscribe to our email newsletter
Preliminary findings from two placebo-controlled human studies on two formulations of M.doc, a haemostatic agent for wound care, indicate that there were no adverse affects and no safety concerns.
Furthermore, following a three week treatment regime, the majority of people in the active treatment groups showed a statistically significant reduction in LDL (“bad”) cholesterol levels. This LDL reduction is comparable to that seen with commercially available sterol-based products.
Previous preclinical results demonstrated that, as well as both reducing LDL cholesterol and improving the HDL/LDL ratio, M.doc also shows significant longer term coronary health benefits in the area of arterial plaque build-up prevention.
The company is now focusing on further efficacy, dosage and timing/phasing studies to determine optimum delivery systems, formats and combinations in both the nutraceutical and pharmaceutical markets.